# Lindy Biosciences, Inc.

> Lindy Biosciences is a Research Triangle Park biotech built on a single stubborn idea: pull the water out of a protein drug fast enough and you get tiny glass-like beads that pour into a syringe. Its Microglassification platform turns biologics that once required an IV drip in a clinic into thick, stable suspensions patients can inject themselves at home - a bet that landed the company a Novartis deal worth up to nearly $1 billion in 2024.

- **Founded:** 2017
- **Headquarters:** Morrisville, North Carolina, United States
- **Founders:** Deborah Bitterfield (CEO & Founder)
- **Team size:** ~24 employees
- **Products:** Microglassification platform, MG Suspensions, Partnering & reformulation services
- **Notable:** Signed a licensing and collaboration agreement with Novartis in Aug 2024 worth up to nearly $1 billion ($20M upfront, up to $934M milestones)., Spun a Duke University lab technique into a licensable commercial platform., Published a peer-reviewed stability comparison of Microglassification vs. lyophilization using a monoclonal antibody (2023).

## Products & services

- **Microglassification platform** — A proprietary process that uses organic solvents to rapidly dehydrate droplets of a protein or antibody solution into solid, spherical, amorphous microbeads with protein density above 1 g/mL - preserving structure while removing water in seconds.
- **MG Suspensions** — High-concentration, low-viscosity injectable suspensions made by suspending microbeads in a carrier fluid, enabling subcutaneous self-administration of biologics that previously required IV infusion.
- **Partnering & reformulation services** — Collaboration and licensing work with pharma and biotech partners to convert IV-delivered biologics into subcutaneous formats, plus applications in sustained-release encapsulation and dry-powder pulmonary delivery.

## Achievements

- Signed a licensing and collaboration agreement with Novartis in Aug 2024 worth up to nearly $1 billion ($20M upfront, up to $934M milestones).
- Spun a Duke University lab technique into a licensable commercial platform.
- Published a peer-reviewed stability comparison of Microglassification vs. lyophilization using a monoclonal antibody (2023).
- Secured Lifecore Biomedical as CDMO for commercial scale-up.
- Reached the Novartis deal after raising only about $8M over the company's life - a capital-efficient path.

## Latest updates

- **2024-08** — Announced licensing and collaboration agreement with Novartis worth up to nearly $1 billion.
- **2024-10** — Selected Lifecore Biomedical as CDMO for process development and commercial scale-up.
- **2025-03** — CEO Deborah Bitterfield served as a panelist at CED Venture Connect in the Research Triangle.
- **2026-01** — Featured in an SSTI/TBED story on NC Biotech-backed startups.

## Links

- Website: https://lindybio.com
- LinkedIn: https://www.linkedin.com/company/lindy-biosciences/

---

Profile page: https://yespress.io/lindy-biosciences-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-20